Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

EV-201 Cohort 2: Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors.

(2021) Arjun Vasant Balar et al.   JOURNAL OF CLINICAL ONCOLOGY

Atezolizumab (atezo) monotherapy versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma (mUC): Clinical outcomes by PD-L1 status in cisplatin (cis)-ineligible pts from the phase III IMvigor130 study.

(2021) Matt D. Galsky et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial

(2021) Joaquim Bellmunt et al.   LANCET ONCOLOGY

Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma

(2021) Thomas Powles et al.   NEW ENGLAND JOURNAL OF MEDICINE

Surgical challenges and considerations in Tri-modal therapy for muscle invasive bladder cancer

(2021) Adam S. Feldman et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Surgical intervention in patients with urothelial carcinoma of the bladder and lymph node metastasis

(2021) Mohammad Abufaraj et al.   CURRENT OPINION IN UROLOGY

Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance)

(2021) Jonathan E. Rosenberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab (pembro) versus investigator’s choice of paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC): 5-year follow-up from the phase 3 KEYNOTE-045 trial.

(2021) Joaquim Bellmunt et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

(2021) Thomas Powles et al.   LANCET ONCOLOGY

Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study

(2021) Arjun V Balar et al.   LANCET ONCOLOGY

Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma

(2021) Dean F. Bajorin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vefora, GETUG-AFU V06 study: Randomized multicenter phase II/III trial of fractionated cisplatin (CI)/gemcitabine (G) or carboplatin (CA)/g in patients (pts) with advanced urothelial cancer (UC) with impaired renal function (IRF)—Results of a planned interim analysis.

(2020) Loic Mourey et al.   JOURNAL OF CLINICAL ONCOLOGY

Study EV-103: Preliminary durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.

(2020) Jonathan E. Rosenberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial

(2020) Alison Birtle et al.   LANCET

ERDAFITINIB in locally advanced or metastatic urothelial carcinoma (mUC): Long-term outcomes in BLC2001.

(2020) Arlene O. Siefker-Radtke et al.   JOURNAL OF CLINICAL ONCOLOGY

Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis.

(2020) Thomas Powles et al.   JOURNAL OF CLINICAL ONCOLOGY

Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial

(2020) Matthew D Galsky et al.   LANCET

The impact of treatment modality on survival in patients with clinical node-positive bladder cancer: results from a multicenter collaboration

(2020) Luca Afferi et al.   WORLD JOURNAL OF UROLOGY

Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer

(2020) Jacqueline Vuky et al.   JOURNAL OF CLINICAL ONCOLOGY

LBA23 Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361

(2020) A. Alva et al.   ANNALS OF ONCOLOGY

Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses

(2020) Christian Pfister et al.   EUROPEAN UROLOGY

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

(2020) Thomas Powles et al.   LANCET ONCOLOGY

Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma

(2020) Thomas Powles et al.   NEW ENGLAND JOURNAL OF MEDICINE

Incidence and outcome of salvage cystectomy after bladder sparing therapy for muscle invasive bladder cancer: a systematic review and meta-analysis

(2020) Victor M. Schuettfort et al.   WORLD JOURNAL OF UROLOGY

Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial

(2020) Stephen A Boorjian et al.   LANCET ONCOLOGY

Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract

(2019) Cora N. Sternberg et al.   EUROPEAN UROLOGY

CALGB 90601 (Alliance): Randomized, double-blind, placebo-controlled phase III trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma.

(2019) Jonathan E. Rosenberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy

(2019) Jonathan E. Rosenberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma

(2019) Yohann Loriot et al.   NEW ENGLAND JOURNAL OF MEDICINE

919PThree-year follow-up from the phase III KEYNOTE-045 trial: Pembrolizumab (Pembro) versus investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC)

(2019) A Necchi et al.   ANNALS OF ONCOLOGY

918PAtezolizumab (atezo) vs chemotherapy (chemo) in patients (pts) with platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): A long-term overall survival (OS) and safety update from the phase III IMvigor211 study

(2019) M S Van der Heijden et al.   ANNALS OF ONCOLOGY

EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees†

(2019) A Horwich et al.   ANNALS OF ONCOLOGY

Clinical outcome after progressing to frontline and second-line Anti–PD-1/PD-L1 in advanced urothelial cancer

(2019) Alfonso Gómez de Liaño Lista et al.   EUROPEAN UROLOGY

Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial

(2019) Thomas Powles et al.   NATURE MEDICINE

The Role of Surgery in Metastatic Bladder Cancer: A Systematic Review

(2018) Mohammad Abufaraj et al.   EUROPEAN UROLOGY

Response Rate to Chemotherapy After Immune Checkpoint Inhibition in Metastatic Urothelial Cancer

(2018) Bernadett Szabados et al.   EUROPEAN UROLOGY

Repeat Transurethral Resection in Non–muscle-invasive Bladder Cancer: A Systematic Review

(2018) Marcus G.K. Cumberbatch et al.   EUROPEAN UROLOGY

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

(2018) Thomas Powles et al.   LANCET

Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

(2018) Manish R Patel et al.   LANCET ONCOLOGY

Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer

(2018) Daniel P. Petrylak et al.   JAMA Oncology

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non–muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial

(2018) Wei Shen Tan et al.   EUROPEAN UROLOGY

Extended Versus Limited Lymph Node Dissection in Bladder Cancer Patients Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial

(2018) Jürgen E. Gschwend et al.   EUROPEAN UROLOGY

Micropapillary Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-analysis of Disease Characteristics and Treatment Outcomes

(2018) Mohammad Abufaraj et al.   EUROPEAN UROLOGY

Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study

(2018) Andrea Necchi et al.   JOURNAL OF CLINICAL ONCOLOGY

Systematic Review on the Fate of the Remnant Urothelium after Radical Cystectomy

(2017) Georgios Gakis et al.   EUROPEAN UROLOGY

Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder

(2017) Thomas Seisen et al.   EUROPEAN UROLOGY

Radical Cystectomy Compared to Combined Modality Treatment for Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis

(2017) Vishal Vashistha et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

(2017) Arjun V Balar et al.   LANCET

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

(2017) Padmanee Sharma et al.   LANCET ONCOLOGY

Bladder cancer diagnosis with CT urography: test characteristics and reasons for false-positive and false-negative results

(2017) Tony W. Trinh et al.   Abdominal Radiology

Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma

(2016) Guru Sonpavde et al.   EUROPEAN UROLOGY

Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa–pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation?

(2016) Richard J. Sylvester et al.   EUROPEAN UROLOGY

EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non–Muscle-invasive Stage Ta–T1 Urothelial Bladder Cancer Patients Treated with 1–3 Years of Maintenance Bacillus Calmette-Guérin

(2016) Samantha Cambier et al.   EUROPEAN UROLOGY

The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part B: Prostate and Bladder Tumours

(2016) Peter A. Humphrey et al.   EUROPEAN UROLOGY

Quantified relations between exposure to tobacco smoking and bladder cancer risk: a meta-analysis of 89 observational studies

(2016) Frits HM van Osch et al.   INTERNATIONAL JOURNAL OF EPIDEMIOLOGY

Definitions, End Points, and Clinical Trial Designs for Non–Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group

(2016) Ashish M. Kamat et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer

(2016) Christophe Massard et al.   JOURNAL OF CLINICAL ONCOLOGY

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

(2016) Jonathan E Rosenberg et al.   LANCET

Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC)

(2016) Francesco Soria et al.   WORLD JOURNAL OF UROLOGY

Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis

(2015) D. Raggi et al.   ANNALS OF ONCOLOGY

Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer

(2015) Matthew D. Galsky et al.   CANCER

Gemcitabine plus split-dose cisplatin could be a promising alternative to gemcitabine plus carboplatin for cisplatin-unfit patients with advanced urothelial carcinoma

(2015) Yi Rang Kim et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Genomic Characterization of Upper Tract Urothelial Carcinoma

(2015) John P. Sfakianos et al.   EUROPEAN UROLOGY

Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3–pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial

(2015) Cora N Sternberg et al.   LANCET ONCOLOGY

Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer

(2015) Faysal A. Yafi et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Critical Analysis of Bladder Sparing with Trimodal Therapy in Muscle-invasive Bladder Cancer: A Systematic Review

(2014) Guillaume Ploussard et al.   EUROPEAN UROLOGY

The Impact of the Extent of Lymphadenectomy on Oncologic Outcomes in Patients Undergoing Radical Cystectomy for Bladder Cancer: A Systematic Review

(2014) Harman M. Bruins et al.   EUROPEAN UROLOGY

Urinary diversion after radical cystectomy for bladder cancer: options, patient selection, and outcomes

(2013) Richard K. Lee et al.   BJU INTERNATIONAL

Long-term Cancer-specific Outcomes of TaG1 Urothelial Carcinoma of the Bladder

(2013) Malte Rieken et al.   EUROPEAN UROLOGY

Adjuvant Chemotherapy for Invasive Bladder Cancer: A 2013 Updated Systematic Review and Meta-Analysis of Randomized Trials

(2013) Jeffrey J. Leow et al.   EUROPEAN UROLOGY

Cisplatin and gemcitabine administered every two weeks in patients with locally advanced or metastatic urothelial carcinoma and impaired renal function

(2012) Rafael Morales-Barrera et al.   EUROPEAN JOURNAL OF CANCER

Prognostic Factors in Upper Urinary Tract Urothelial Carcinomas: A Comprehensive Review of the Current Literature

(2012) Giovanni Lughezzani et al.   EUROPEAN UROLOGY

Lymph Node–Positive Bladder Cancer Treated With Radical Cystectomy and Lymphadenectomy: Effect of the Level of Node Positivity

(2012) Tatum V. Tarin et al.   EUROPEAN UROLOGY

Pathologic Nodal Staging Score for Bladder Cancer: A Decision Tool for Adjuvant Therapy After Radical Cystectomy

(2012) Shahrokh F. Shariat et al.   EUROPEAN UROLOGY

Epidemiology and Risk Factors of Urothelial Bladder Cancer

(2012) Maximilian Burger et al.   EUROPEAN UROLOGY

Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guérin in Intermediate- and High-risk Ta, T1 Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of Maintenance

(2012) Jorg Oddens et al.   EUROPEAN UROLOGY

Stage-specific impact of extended versus standard pelvic lymph node dissection in radical cystectomy

(2012) Giuseppe Simone et al.   INTERNATIONAL JOURNAL OF UROLOGY

Randomized Phase III Study Comparing Paclitaxel/Cisplatin/ Gemcitabine and Gemcitabine/Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Cancer Without Prior Systemic Therapy: EORTC Intergroup Study 30987

(2012) Joaquim Bellmunt et al.   JOURNAL OF CLINICAL ONCOLOGY

Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer

(2012) Nicholas D. James et al.   NEW ENGLAND JOURNAL OF MEDICINE

Upper urinary tract urothelial cell carcinoma: location as a predictive factor for concomitant bladder carcinoma

(2012) Marco Cosentino et al.   WORLD JOURNAL OF UROLOGY

Clinical Nodal Staging Scores for Bladder Cancer: A Proposal for Preoperative Risk Assessment

(2011) Shahrokh F. Shariat et al.   EUROPEAN UROLOGY

Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy

(2011) Matthew D. Galsky et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986

(2011) Maria De Santis et al.   JOURNAL OF CLINICAL ONCOLOGY

Radiotherapy With Concurrent Carbogen and Nicotinamide in Bladder Carcinoma

(2010) Peter J. Hoskin et al.   JOURNAL OF CLINICAL ONCOLOGY

Does preoperative symptom classification impact prognosis in patients with clinically localized upper-tract urothelial carcinoma managed by radical nephroureterectomy?

(2010) Jay D. Raman et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Troubling Outcomes From Population-level Analysis of Surgery for Upper Tract Urothelial Carcinoma

(2010) Robert Abouassaly et al.   UROLOGY

Carcinoma of the upper urinary tract

(2009) Brant A. Inman et al.   CANCER

Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration

(2009) Vitaly Margulis et al.   CANCER

An Individual Patient Data Meta-Analysis of the Long-Term Outcome of Randomised Studies Comparing Intravesical Mitomycin C versus Bacillus Calmette-Guérin for Non–Muscle-Invasive Bladder Cancer

(2009) Per-Uno Malmström et al.   EUROPEAN UROLOGY

FDG-PET/CT for the Preoperative Lymph Node Staging of Invasive Bladder Cancer

(2009) Greet Swinnen et al.   EUROPEAN UROLOGY

Risk of concomitant carcinoma in situ determining biopsy candidates among primary non-muscle-invasive bladder cancer patients: Retrospective analysis of 173 Japanese cases

(2009) Tomohiko Hara et al.   INTERNATIONAL JOURNAL OF UROLOGY

Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract

(2009) Joaquim Bellmunt et al.   JOURNAL OF CLINICAL ONCOLOGY

Recurrence at Three Months and High-grade Recurrence as Prognostic Factor of Progression in Multivariate Analysis of T1G2 Bladder Tumors

(2009) Juan Palou et al.   UROLOGY

A Population-based Assessment of Perioperative Mortality After Nephroureterectomy for Upper-tract Urothelial Carcinoma

(2009) Claudio Jeldres et al.   UROLOGY